9 results about "RAD51" patented technology

The invention relates to the technical field of biological medicine, and particularly discloses a small-molecule targeted degradation agent targeting RAD51 protein, a pharmaceutical composition and application. The small-molecule targeted degradation agent targeting the RAD51 protein, provided by the invention, is used for preparing a medicine for treating and / or preventing prostatic cancer. The chemical structure of the micromolecule targeted degradation agent is shown in the specification.

The invention discloses a pharmaceutical composition for treating KRAS G12D mutation cancer and application of the pharmaceutical composition, and belongs to the technical field of biological medicine. The pharmaceutical composition comprises a KRAS G12D inhibitor and a PARP (poly-ADP-ribose polymerase) inhibitor. The core of the invention lies in that a KRAS G12D inhibitor (such as MRTX1133) can down-regulate expression of homologous recombination (HR) repair related proteins (such as BRCA1, RAD51 and RPA32) and induce HR defects, so that tumor cells carrying KRAS G12D mutation have high sensitivity to a PARP inhibitor (such as Olaparib), and a synthetic lethal effect is formed. The combined strategy not only shows synergistic anti-tumor activity in a model sensitive to the KRAS G12D inhibitor, but also is effective in a model resistant to the KRAS G12D inhibitor. The invention provides a new effective scheme for treating cancers such as pancreatic ductal adenocarcinoma with KRAS G12D mutation, and is expected to expand the applicable patient population of the PARP inhibitor.

The present application belongs to the field of microbial metabolic engineering and industrial microorganism technology, and particularly relates to a method for stably integrating exogenous DNA into Pseudozyma roseolata, an iterative gene editing method and application thereof. The preservation number of the strain MYL-2 is CCTCC M 20252968, and the strain can efficiently accumulate oil under nitrogen-limited culture conditions, the main fatty acid components in the cells are C16-C18 fatty acids, and the strain has application potential as a microbial oil production strain. The present application provides a method for stably integrating exogenous DNA into Pseudozyma roseolata, and constructs a recombinant expression vector pNFH-loxp-RAD51 and a Cre recombination vector containing a loxP site, and for the first time, precise removal and repeated use of a screening marker mediated by a Cre-LoxP system are realized in the strain, thereby laying a foundation for multi-round gene editing and efficient engineering modification of the strain.

This invention relates to the field of biomedical technology, disclosing succinylated modified RAD51 protein, formulations for promoting RAD51 succinylation, and their applications. The method includes: seeding and culturing cells and transfecting them with a tagged RAD51 expression plasmid; adding sodium succinate and an HDAC11 inhibitor to the culture medium for continued culturing to allow intracellular modification accumulation; collecting the supernatant after cell lysis and incubating it with magnetic beads containing anti-tag antibodies under cold conditions; washing and eluting with an elution buffer containing the tagged peptide; performing immunoblotting analysis using antibodies that specifically recognize the modified site to obtain the succinylated modified RAD51 protein. This invention, by adding sodium succinate and an HDAC11 inhibitor, provides a substrate and blocks the demodification pathway. Combined with magnetic bead purification and competitive elution, it avoids disrupting the protein conformation, obtaining a protein that retains its native activity and has a high level of modification, providing a core component for screening targeted drugs.

The present invention relates to a CRISPR Cas9 vector and its uses, and more specifically, to a CRISPR Cas9 vector with increased gene editing efficiency. The CRISPR Cas9 vector of the present invention expresses the RAD51 gene, and when the CRISPR Cas9 vector of the present invention is used, the efficiency of gene editing increases by more than 2 times, so genes can be edited with higher efficiency and accuracy.

An assay system and method for generating quantitative data for a subject and a method for treating prostate cancer in a subject by determining an expression level of a biomarker panel in a sample obtained from the subject, the biomarker panel including the genes CDC45, CENPI, CLSPN, ERCC6L, EXO1, NCAPG, BUB1B, CDK1, NUSAP1, RAD51, and RRM2 and optionally E2F7 and / or GSG2, wherein the expression level is obtained by measuring expression of the biomarker panel in the sample, and wherein the subject has a cancer, or is suspected of having a cancer. The cancer may be, for example, prostate cancer, brain cancer, lung cancer, breast cancer, bladder cancer, or ovarian cancer.

The present application belongs to the technical field of anti-tumor drug design, and particularly relates to a nanoparticle containing cisplatin-linoleic acid and SN38-linoleic acid, wherein the nanoparticle is formed by wrapping cisplatin-linoleic acid and SN38-linoleic acid with an amphiphilic polymer, and the amphiphilic polymer is distearoyl phosphatidyl ethanolamine-polyethylene glycol. By wrapping cisplatin-linoleic acid and SN38-linoleic acid prodrug molecules with the amphiphilic polymer, the water solubility of the drug molecules can be improved, and the in-vivo synchronous delivery and transportation of the cisplatin-linoleic acid and SN38-linoleic acid prodrug molecules can be realized, so that the synergistic anti-tumor effect can be achieved. In the mechanism, it is proved that the SN38-linoleic acid prodrug in the co-wrapped nanoparticle can not only cause DNA damage, but also inhibit the DNA damage repair protein Rad51, so as to increase the drug efficacy of the cisplatin-linoleic acid prodrug in drug-resistant tumors, and achieve the best tumor killing effect.

The invention provides application of MACIR protein in preparation of a DNA (deoxyribonucleic acid) repair medicine and the medicine of the MACIR protein, the MACIR protein serves as an adapter protein of a FIGNL1-FIRRM complex, and repair of cross-linking between DNA chains is promoted by enhancing the dissociation activity of the complex on RAD51 nucleoprotein filaments. In the research, the MACIR is identified as the potential adapter protein of the FIGNL1-FIRRM unfolding enzyme by combining proteomics analysis and genetic interaction database screening. A further research shows that the MACIR can directly interact with the FIRRM and form a ternary complex with the FIGNL1. Functionally, the MACIR enhances the anti-recombinase activity of a FIGNL1-FIRRM complex, and promotes the dissociation of RAD51 from DNA, thereby helping cells to cope with the damage of cross-linking (ICLs) between DNA chains induced by aldehydes or platinum drugs and maintaining the stability of a genome.

The invention discloses pichia pastoris engineering bacteria with high homologous recombination efficiency as well as a construction method and application of the pichia pastoris engineering bacteria. According to the invention, a ku70 gene, a ku80 gene, a Dnl4 gene or a chr3-0308 gene in pichia pastoris are knocked out, and an RAD50 gene, an RAD51 gene, an RAD52 gene, an RAD57 gene, an SAE2 gene and an MRE11 gene are over-expressed, so that the pichia pastoris engineering strain with high homologous integration capability and high growth efficiency is obtained; in addition, it is proved that the homologous recombination activity of pichia pastoris can be improved by overexpressing the homologous recombination related protein and knocking out the non-homologous end connection related protein.